XARELTO IS UNSAFE BECAUSE OF BLEEDING RISKS – AND THERE IS NO ANTIDOTE

Manufactured in the United States by Bayer and marketed by Janssen Pharmaceuticals, Xarelto (Rivaroxaban) is currently prescribed by physicians to their patients as an anti-coagulant.  First introduced in 2011, the primary target of Xarelto was blood clots in knee and hip replacement patients.  Secondarily it is being promoted as a way to prevent blood clots attributed to atrial fibrillation.

Unfortunately, a potential side effect of anti-coagulants is bleeding.  Uncontrolled bleeding can be fatal. What sets Xarelto apart from the long time drugs like Coumadin, which uses Vitamin K as an antidote for bleeding, is that with Xarelto there is NO ANTIDOTE.

A 2012 article in The Huffington Post detailed specific concerns by top heart specialists relating to the use of Xarelto.  Despite those concerns and the ever rising number of injuries and deaths associated with Xarelto it is still on the market.  It is one of the rare drugs that has serious and fatal side effects, and yet has no known antidote.

The first bellwether trial is scheduled to begin in Louisiana in 2016.

If you or a loved one suffered from severe bleeding after taking Xarelto, please contact the Levensten Law Firm at 215-545-5600 or on our home page, or at www.xareltoinjurylawyer.com to learn how to file a claim for compensation for your injuries.